CERUS CORP · Data as of 2026-09-08
2026
Looking ahead, we have a meaningful catalyst path in 2026, spanning anticipated regulatory, clinical, and pipeline milestones, including ongoing INTERCEPT RBC regulatory review in Europe, the Phase 3 RedeS readout in the U.S., and the planned U.S. PMA submission for our new INT200 illumination device.Source filing
H2 2026
Results from the Phase 3 RedeS study of the INTERCEPT Blood System for Red Blood Cells (RBCs) in anemia patients expected in the second half of 2026.Source filing
H2 2026
We anticipate completion of the RedeS clinical trial enrollment by the end of 2025 and completion of the trial in the second half of 2026.Source filing
late 2026
The preliminary results from the RedeS study are expected in late 2026, and if positive, are expected to support our chronic use assessment in our planned modular premarket approval, or PMA, application for the red blood cell system that we plan to submit to the FDA.Source filing
early 2027
Given review timelines, a regulatory decision is anticipated in early 2027.Source filing